{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:07:31Z","timestamp":1788671251688,"version":"build-2803163510"},"reference-count":36,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Johannes Kepler University Open Access Publishing Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: The clinical spectrum of fibrotic interstitial lung diseases (ILDs) is highly heterogeneous. We aimed to evaluate the prognostic value of widely available baseline biomarkers for the improvement of lung function in patients with fibrotic ILDs. Methods: This registry-based study included 142 patients with fibrotic ILDs as defined by the presence of reticulation, traction bronchiectasis or honeycombing on initial high-resolution computed tomography (HRCT). Functional improvement at 1 year was defined as a relative increase of 5% in forced vital capacity (FVC) or of 10% in diffusion capacity for carbon monoxide (DLCO). The prognostic value of baseline biomarkers was evaluated for all patients and the subgroup with anti-inflammatory treatment. Results: At one year, 44 patients showed improvement while 73 showed disease progression. Multivariate analyses found prognostic significance for age &lt; 60 years (OR 5.4; 95%CI 1.9\u201315.4; p = 0.002), lactate dehydrogenase (LDH) &gt;250 U\/L (OR 2.5; 95%CI 1.1\u20135.8; p = 0.043) and blood monocyte count &lt; 0.8 G\/L (OR 3.5; 95%CI 1.1\u201311.3; p = 0.034). In 84 patients undergoing anti-inflammatory treatment, multivariate analysis revealed age &lt; 60 years (OR 8.5 (95%CI 2.1\u201333.4; p = 0.002) as the only significant variable. Conclusion: Younger age, a higher LDH and lower blood monocyte count predicted functional improvement in fibrotic ILD patients, while in those treated with anti-inflammatory drugs, only age had significant implications.<\/jats:p>","DOI":"10.3390\/diagnostics14141544","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T12:29:43Z","timestamp":1721219383000},"page":"1544","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Functional Improvement at One Year in Fibrotic Interstitial Lung Diseases\u2014Prognostic Value of Baseline Biomarkers and Anti-Inflammatory Therapies"],"prefix":"10.3390","volume":"14","author":[{"given":"Guangyu","family":"Shao","sequence":"first","affiliation":[{"name":"Kepler University Hospital, 4020 Linz, Austria"},{"name":"Faculty of Medicine, Johannes Kepler University, 4040 Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Th\u00f6ne","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Johannes Kepler University, 4040 Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4158-0350","authenticated-orcid":false,"given":"Bernhard","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Kepler University Hospital, 4020 Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3365-3449","authenticated-orcid":false,"given":"Bernd","family":"Lamprecht","sequence":"additional","affiliation":[{"name":"Kepler University Hospital, 4020 Linz, Austria"},{"name":"Faculty of Medicine, Johannes Kepler University, 4040 Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3098-1554","authenticated-orcid":false,"given":"David","family":"Lang","sequence":"additional","affiliation":[{"name":"Kepler University Hospital, 4020 Linz, Austria"},{"name":"Faculty of Medicine, Johannes Kepler University, 4040 Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(22)01052-2","article-title":"Interstitial lung diseases","volume":"400","author":"Wijsenbeek","year":"2022","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","article-title":"Progressive fibrosing interstitial lung disease: Clinical uncertainties, consensus recommendations, and research priorities","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1080\/03007995.2019.1647040","article-title":"Progressive fibrosing interstitial lung diseases: Current practice in diagnosis and management","volume":"35","author":"Wijsenbeek","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.resinv.2023.01.007","article-title":"Interstitial pneumonia with autoimmune features and histologic usual interstitial pneumonia treated with anti-fibrotic versus immunosuppressive therapy","volume":"61","author":"Yamano","year":"2023","journal-title":"Respir. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(12)61079-4","article-title":"Interstitial lung disease in connective tissue disorders","volume":"380","author":"Fischer","year":"2012","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1800692","DOI":"10.1183\/13993003.00692-2018","article-title":"What\u2019s in a name? that which we call IPF, by any other Name would act the same","volume":"51","author":"Wells","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1513\/AnnalsATS.202103-343OC","article-title":"Nintedanib in progressive pulmonary fibrosis: A systematic review and meta-analysis","volume":"19","author":"Ghazipura","year":"2022","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2103187","DOI":"10.1183\/13993003.03187-2021","article-title":"Progressive pulmonary fibrosis: An expert group consensus statement","volume":"61","author":"Rajan","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_11","first-page":"75","article-title":"Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCISTM)","volume":"35","author":"Distler","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.13-1474","article-title":"Predicting survival across chronic interstitial lung disease: The ILD-GAP model","volume":"145","author":"Ryerson","year":"2014","journal-title":"Chest"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S2213-2600(19)30059-1","article-title":"Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: A prospective validation study","volume":"7","author":"Raghu","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(21)00503-8","article-title":"Proteomic biomarkers of progressive fibrosing interstitial lung disease: A multicentre cohort analysis","volume":"10","author":"Bowman","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1479973120967025","DOI":"10.1177\/1479973120967025","article-title":"Computed tomography findings as determinants of pulmonary function tests in fibrotic interstitial lung diseases-network-analyses and multivariate models","volume":"17","author":"Lang","year":"2020","journal-title":"Chron. Respir. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/annrheumdis-2021-eular.1067","article-title":"Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database","volume":"80","author":"Allanore","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (strobe) statement: Guidelines for reporting observational studies","volume":"61","author":"Altman","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.chest.2019.10.017","article-title":"An algorithmic approach to the interpretation of diffuse lung disease on chest ct imaging: A theory of almost everything","volume":"157","author":"Gruden","year":"2020","journal-title":"Chest"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Shao, G., Hawle, P., Akbari, K., Horner, A., Hintenberger, R., Kaiser, B., Lamprecht, B., and Lang, D. (2022). Clinical, imaging, and blood biomarkers to assess 1-year progression risk in fibrotic interstitial lung diseases-development and validation of the honeycombing, traction bronchiectasis, and monocyte (HTM)-score. Front. Med., 9.","DOI":"10.3389\/fmed.2022.1043720"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","article-title":"A multidimensional index and staging system for idiopathic pulmonary fibrosis","volume":"156","author":"Ley","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Dhooria, S., Agarwal, R., Sehgal, I.S., Prasad, K.T., Garg, M., Bal, A., Aggarwal, A.N., and Behera, D. (2018). Spectrum of interstitial lung diseases at a tertiary center in a developing country: A study of 803 subjects. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0191938"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Joung, K.I., Park, H., Park, S., Shin, J.Y., and Kim, Y.H. (2023). Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: A population-based study. BMC Pulm. Med., 23.","DOI":"10.1186\/s12890-023-02373-z"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1183\/13993003.01504-2015","article-title":"Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada","volume":"48","author":"Hopkins","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1378\/chest.09-1002","article-title":"Incidence, Prevalence, and Clinical Course of Idiopathic Pulmonary Fibrosis: A Population-Based Study","volume":"137","author":"Daniels","year":"2010","journal-title":"Chest"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/thx.2010.148031","article-title":"The Rising Incidence of Idiopathic pulmonary fibrosis in the U.K","volume":"66","author":"Navaratnam","year":"2011","journal-title":"Thorax"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1602419","DOI":"10.1183\/13993003.02419-2016","article-title":"Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of greater Paris","volume":"50","author":"Duchemann","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s10067-021-05984-1","article-title":"Risk factors for progression of interstitial lung disease in sj\u00f6gren\u2019s syndrome: A single-centered, retrospective study","volume":"41","author":"He","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Cao, M., Sheng, J., Qiu, X., Wang, D., Wang, D., Wang, Y., Xiao, Y., and Cai, H. (2019). Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: A population-based study. BMC Pulm. Med., 19.","DOI":"10.1186\/s12890-019-0960-1"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s10067-023-06570-3","article-title":"Prediction of progressive pulmonary fibrosis in patients with anti-synthetase syndrome-associated interstitial lung disease","volume":"42","author":"Fu","year":"2023","journal-title":"Clin. Rheumatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S2213-2600(18)30508-3","article-title":"Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: A retrospective, multicentre cohort study","volume":"7","author":"Scott","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1164\/rccm.202003-0669OC","article-title":"Monocyte count as a prognostic biomarker in patients with idiopathic pulmonary fibrosis","volume":"204","author":"Kreuter","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.immuni.2016.02.015","article-title":"Macrophages in tissue repair, regeneration, and fibrosis","volume":"44","author":"Wynn","year":"2016","journal-title":"Immunity"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"240ra76","DOI":"10.1126\/scitranslmed.3007096","article-title":"Chitinase 3-like 1 suppresses injury and promotes fibroproliferative responses in mammalian lung fibrosis","volume":"6","author":"Zhou","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1084\/jem.20162152","article-title":"Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span","volume":"214","author":"Misharin","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Ehrchen, J.M., Roth, J., and Barczyk-Kahlert, K. (2019). More than suppression: Glucocorticoid action on monocytes and macrophages. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02028"},{"key":"ref_36","first-page":"7561661","article-title":"Methotrexate treatment suppresses monocytes in nonresponders to pneumococcal conjugate vaccine in rheumatoid arthritis patients","volume":"2022","author":"Nived","year":"2022","journal-title":"J. Immunol. Res."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/14\/1544\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:18:17Z","timestamp":1760109497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/14\/1544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":36,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["diagnostics14141544"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics14141544","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,17]]}}}